Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent

Research methods to change clinical practice for patients with rare cancers

(2016) Lucinda Billingham et al.   LANCET ONCOLOGY

Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia

(2015) E. Estey et al.   BLOOD

Preclinical efficacy of MEK inhibition in Nras-mutant AML

(2014) M. R. Burgess et al.   BLOOD

Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide

(2014) Yun-Gyoo Lee et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

(2014) Vivek Subbiah et al.   Journal of Hematology & Oncology

Acquired isochromosome 12p, somatic TP53 and PTEN mutations, and a germline ATM variant in an adolescent male with concurrent acute megakaryoblastic leukemia and mediastinal germ cell tumor

(2014) Benjamin R. Oshrine et al.   Cancer Genetics

Links between mutant p53 and genomic instability

(2011) Walter Hanel et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Successful treatment of a patient with Klinefelter's syndrome complicated by mediastinal germ cell tumor and AML(M7)

(2008) H Hiramatsu et al.   BONE MARROW TRANSPLANTATION